LL-III/25

General Information


DRACP ID  DRACP00385

Peptide Name   LL-III/25

Sequence  vnwkkllgkllkvvk

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=4±2 µM MTT assay 48 h 1
SW480 Colon adenocarcinoma Carcinoma IC50=20 µM MTT assay 48 h 1
CCRF-CEM Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50=4 µM MTT assay 48 h 1

Hemolytic Activity  Rat erythrocytes: IC50>200 μM

Normal (non-cancerous) Cytotoxicity  HUVEC: IC50=12±3 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  D



Physicochemical Information


Formula  H-28O-14

Absent amino acids  ACDEFGHIKLMNPQRSTVWY

Common amino acids  ACDEFGHIKLMNPQRSTVWYX

Mass  -234

Pl  6.11

Basic residues  0

Acidic residues  0

Hydrophobic residues  0

Net charge  0

Boman Index  0

Hydrophobicity  0

Aliphatic Index  0

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22100226

Title  Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells

Doi 10.1016/j.peptides.2011.11.002

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.